2) Fusion protein: Use fusion partners such as albumin and Fc to increase the molecular weight of the drug, reduce rapid filtration by the kidneys, coordinate with other action mechanisms to increase the circulation time in the body
10.1016/j.comppsych.2019.152156 Compr
125 VERTIS-CVOT (URL: Unique identifier: NCT0198688) is a placebo-controlled RCT to assess CV outcomes following treatment with ertugliflozin (5 or 15 mg once daily) in patients with T2DM and established vascular disease, a population almost similar to that enrolled in EMPA-REG OUTCOME
Another concern is overtreatment
SLU-PP-332 is a novel oral peptide designed to mimic the effects of aerobic exercise at the cellular level by activating ERR, offering benefits for metabolism and mitochondrial health without the need for intensive training
There is human evidence that Akkermansia can raise GLP-1, described above, but the broader metabolic benefits in that trial were not universal and some people will not see a measurable change
